{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:08Z","timestamp":1792783268439,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant No. 82160583"],"award-info":[{"award-number":["grant No. 82160583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Fundamental Research Projects","award":["202101AY070001-231"],"award-info":[{"award-number":["202101AY070001-231"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04710-z","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T06:13:55Z","timestamp":1754892835000},"page":"749-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognosis of radical prostatectomy combined with pelvic lymph node dissection in patients with intermediate- and high-risk prostate cancer: a systematic review and single-arm meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Zhengyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"1","key":"4710_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"4710_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K et al (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011","journal-title":"Ann Oncol"},{"issue":"3","key":"4710_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MOU.0b013e328338405d","volume":"20","author":"ME Hyndman","year":"2010","unstructured":"Hyndman ME, Mullins JK, Pavlovich CP (2010) Pelvic node dissection in prostate cancer: extended, limited, or not at all? Curr Opin Urol 20(3):211\u2013217. https:\/\/doi.org\/10.1097\/MOU.0b013e328338405d","journal-title":"Curr Opin Urol"},{"issue":"6","key":"4710_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.eururo.2009.03.012","volume":"55","author":"A Briganti","year":"2009","unstructured":"Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251\u20131265. https:\/\/doi.org\/10.1016\/j.eururo.2009.03.012","journal-title":"Eur Urol"},{"issue":"2","key":"4710_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"issue":"4","key":"4710_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","volume":"4","author":"KA Touijer","year":"2021","unstructured":"Touijer KA, Sjoberg DD, Benfante N et al (2021) Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial. Eur Urol Oncol 4(4):532\u2013539. https:\/\/doi.org\/10.1016\/j.euo.2021.03.006","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"4710_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/ju.0000000000000504","volume":"203","author":"F Preisser","year":"2020","unstructured":"Preisser F, van den Bergh RCN, Gandaglia G et al (2020) Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with D\u2019Amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol 203(2):338\u2013343. https:\/\/doi.org\/10.1097\/ju.0000000000000504","journal-title":"J Urol"},{"key":"4710_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235803","author":"S Namiki","year":"2022","unstructured":"Namiki S, Kawase M, Ebara S et al (2022) Pelvic lymphadenectomy may not improve biochemical recurrence-free survival in patients with prostate cancer treated with robot-assisted radical prostatectomy in Japan (The MSUG94 Group). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14235803","journal-title":"Cancers (Basel)."},{"issue":"2","key":"4710_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.euo.2021.02.001","volume":"4","author":"GE Cacciamani","year":"2021","unstructured":"Cacciamani GE, Maas M, Nassiri N et al (2021) Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis. Eur Urol Oncol 4(2):134\u2013149. https:\/\/doi.org\/10.1016\/j.euo.2021.02.001","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"4710_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1464-410X.2010.10016.x","volume":"108","author":"R Schiavina","year":"2011","unstructured":"Schiavina R, Manferrari F, Garofalo M et al (2011) The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. BJU Int 108(8):1262\u20131268. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10016.x","journal-title":"BJU Int"},{"issue":"5","key":"4710_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","volume":"79","author":"JFP Lestingi","year":"2021","unstructured":"Lestingi JFP, Guglielmetti GB, Trinh QD et al (2021) Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol 79(5):595\u2013604. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.040","journal-title":"Eur Urol"},{"issue":"4","key":"4710_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1464-410X.2009.09161.x","volume":"106","author":"CG Eden","year":"2010","unstructured":"Eden CG, Arora A, Rouse P (2010) Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate- and high-risk prostate cancer. BJU Int 106(4):537\u2013542. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09161.x","journal-title":"BJU Int"},{"issue":"2","key":"4710_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1464-410X.2012.11765.x","volume":"112","author":"KH Kim","year":"2013","unstructured":"Kim KH, Lim SK, Kim HY et al (2013) Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis. BJU Int 112(2):216\u2013223. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11765.x","journal-title":"BJU Int"},{"key":"4710_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4710_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"issue":"2","key":"4710_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"4710_CR17","doi-asserted-by":"publisher","first-page":"1218258","DOI":"10.3389\/fimmu.2023.1218258","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Mo W, Jiang W et al (2023) The benefit and risk of PD-1\/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials. Front Immunol 14:1218258. https:\/\/doi.org\/10.3389\/fimmu.2023.1218258","journal-title":"Front Immunol"},{"key":"4710_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"4710_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4710_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"4710_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"issue":"11","key":"4710_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119\u20131129. https:\/\/doi.org\/10.1016\/s0895-4356(00)00242-0","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4710_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.23736\/s0393-2249.16.02799-5","volume":"69","author":"S Albisinni","year":"2017","unstructured":"Albisinni S, Aoun F, Led D et al (2017) Comparing conventional laparoscopic to robotic-assisted extended pelvic lymph node dissection in men with intermediate and high-risk prostate cancer: a matched-pair analysis. Minerva Urol Nefrol 69(1):101\u2013107. https:\/\/doi.org\/10.23736\/s0393-2249.16.02799-5","journal-title":"Minerva Urol Nefrol"},{"issue":"1","key":"4710_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41391-021-00452-y","volume":"25","author":"DJH Baas","year":"2022","unstructured":"Baas DJH, Schilham M, Hermsen R et al (2022) Preoperative PSMA-PET\/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostatic Dis 25(1):65\u201370. https:\/\/doi.org\/10.1038\/s41391-021-00452-y","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4710_CR25","first-page":"9340","volume":"25","author":"A Chenam","year":"2018","unstructured":"Chenam A, Ruel N, Pal S et al (2018) Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer. Can J Urol 25(3):9340\u20139348","journal-title":"Can J Urol"},{"issue":"5","key":"4710_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bju.16117","volume":"132","author":"P de Pablos-Rodr\u00edguez","year":"2023","unstructured":"de Pablos-Rodr\u00edguez P, Claps F, Rebez G et al (2023) Personalised indocyanine-guided lymphadenectomy for prostate cancer: a randomised clinical trial. BJU Int 132(5):591\u2013599. https:\/\/doi.org\/10.1111\/bju.16117","journal-title":"BJU Int"},{"issue":"3\u20134","key":"4710_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5489\/cuaj.2485","volume":"9","author":"GB Di Pierro","year":"2015","unstructured":"Di Pierro GB, Grande P, Wirth JG et al (2015) Extended pelvic lymph node dissection at the time of robot-assisted radical prostatectomy: impact of surgical volume on efficacy and complications in a single-surgeon series. Can Urol Assoc J 9(3\u20134):107\u2013113. https:\/\/doi.org\/10.5489\/cuaj.2485","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"4710_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4103\/1008-682x.133319","volume":"16","author":"KH Kim","year":"2014","unstructured":"Kim KH, Lim SK, Koo KC et al (2014) Extended lymph node dissection in robot-assisted radical prostatectomy: lymph node yield and distribution of metastases. Asian J Androl 16(6):824\u2013828. https:\/\/doi.org\/10.4103\/1008-682x.133319","journal-title":"Asian J Androl"},{"issue":"11","key":"4710_CR29","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1159\/000526113","volume":"106","author":"L Krieger","year":"2022","unstructured":"Krieger L, Holze S, Mende M et al (2022) Extended pelvic lymph node dissection does not affect functional outcomes during bilateral nerve-sparing radical prostatectomy. Urol Int 106(11):1136\u20131144. https:\/\/doi.org\/10.1159\/000526113","journal-title":"Urol Int"},{"issue":"1","key":"4710_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bju.15492","volume":"129","author":"D Meijer","year":"2022","unstructured":"Meijer D, van Leeuwen PJ, Donswijk ML et al (2022) Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU Int 129(1):54\u201362. https:\/\/doi.org\/10.1111\/bju.15492","journal-title":"BJU Int"},{"issue":"6","key":"4710_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/pros.23486","volume":"78","author":"J Miki","year":"2018","unstructured":"Miki J, Yanagisawa T, Tsuzuki S et al (2018) Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer. Prostate 78(6):419\u2013425. https:\/\/doi.org\/10.1002\/pros.23486","journal-title":"Prostate"},{"issue":"3","key":"4710_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11701-022-01480-z","volume":"17","author":"A \u00d6zkan","year":"2023","unstructured":"\u00d6zkan A, K\u00f6seo\u011flu E, Canda AE et al (2023) Fluorescence-guided extended pelvic lymphadenectomy during robotic radical prostatectomy. J Robot Surg 17(3):885\u2013890. https:\/\/doi.org\/10.1007\/s11701-022-01480-z","journal-title":"J Robot Surg"},{"issue":"12","key":"4710_CR33","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/ans.13035","volume":"85","author":"A Picardo","year":"2015","unstructured":"Picardo A, Vivian J (2015) Extended pelvic lymph node dissection for clinically localized prostate cancer: a West Australian experience. ANZ J Surg 85(12):936\u2013940. https:\/\/doi.org\/10.1111\/ans.13035","journal-title":"ANZ J Surg"},{"issue":"11","key":"4710_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11255-020-02554-3","volume":"52","author":"A Tafuri","year":"2020","unstructured":"Tafuri A, Amigoni N, Rizzetto R et al (2020) Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. Int Urol Nephrol 52(11):2097\u20132105. https:\/\/doi.org\/10.1007\/s11255-020-02554-3","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"4710_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1464-410X.2012.11788.x","volume":"112","author":"BE Yuh","year":"2013","unstructured":"Yuh BE, Ruel NH, Mejia R et al (2013) Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU Int 112(1):81\u201388. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11788.x","journal-title":"BJU Int"},{"issue":"5","key":"4710_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.eururo.2012.01.048","volume":"61","author":"BE Yuh","year":"2012","unstructured":"Yuh BE, Ruel NH, Mejia R et al (2012) Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer. Eur Urol 61(5):1004\u20131010. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.048","journal-title":"Eur Urol"},{"issue":"4","key":"4710_CR37","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/s0022-5347(05)00685-3","volume":"175","author":"TA Masterson","year":"2006","unstructured":"Masterson TA, Bianco FJ Jr, Vickers AJ et al (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175(4):1320\u20131324. https:\/\/doi.org\/10.1016\/s0022-5347(05)00685-3","journal-title":"J Urol"},{"issue":"Jul","key":"4710_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.urology.2006.01.055","volume":"68","author":"SA Joslyn","year":"2006","unstructured":"Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68(Jul):121\u2013125. https:\/\/doi.org\/10.1016\/j.urology.2006.01.055","journal-title":"Urology"},{"issue":"10","key":"4710_CR39","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1464-410X.2010.09395_3.x","volume":"105","author":"C Eden","year":"2010","unstructured":"Eden C, Arora A (2010) The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int 105(10):1479\u20131480. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09395_3.x","journal-title":"BJU Int"},{"issue":"4","key":"4710_CR40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/01.ju.0000155533.93528.4c","volume":"173","author":"DS DiMarco","year":"2005","unstructured":"DiMarco DS, Zincke H, Sebo TJ et al (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173(4):1121\u20131125. https:\/\/doi.org\/10.1097\/01.ju.0000155533.93528.4c","journal-title":"J Urol"},{"issue":"1","key":"4710_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","volume":"53","author":"A Mattei","year":"2008","unstructured":"Mattei A, Fuechsel FG, Bhatta Dhar N et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53(1):118\u2013125. https:\/\/doi.org\/10.1016\/j.eururo.2007.07.035","journal-title":"Eur Urol"},{"issue":"3","key":"4710_CR42","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/js9.0000000000000997","volume":"110","author":"G Ding","year":"2024","unstructured":"Ding G, Tang G, Wang T et al (2024) A comparative analysis of perioperative complications and biochemical recurrence between standard and extended pelvic lymph node dissection in prostate cancer patients undergoing radical prostatectomy: a systematic review and meta-analysis. Int J Surgery (London, England) 110(3):1735\u20131743. https:\/\/doi.org\/10.1097\/js9.0000000000000997","journal-title":"Int J Surgery (London, England)"},{"issue":"2","key":"4710_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.euf.2024.01.002","volume":"10","author":"DE Hinojosa-Gonzalez","year":"2024","unstructured":"Hinojosa-Gonzalez DE, Nolazco JI, Saffati G et al (2024) Oncologic outcome of the extent of pelvic lymph node dissection during radical prostatectomy: a systematic review, meta-analysis, and network analysis. Eur Urol Focus 10(2):234\u2013241. https:\/\/doi.org\/10.1016\/j.euf.2024.01.002","journal-title":"Eur Urol Focus"},{"key":"4710_CR44","doi-asserted-by":"publisher","unstructured":"Solomonidou N, Germanou D, Strouthos I, et al. (2023) PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA\u2009<\u200902 ng\/ml. Eur J Nucl Med Mol Imaging 50(8):2529-2536. https:\/\/doi.org\/10.1007\/s00259-023-06185-5","DOI":"10.1007\/s00259-023-06185-5"},{"issue":"2","key":"4710_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bju.14944","volume":"125","author":"HB Luiting","year":"2020","unstructured":"Luiting HB, van Leeuwen PJ, Busstra MB et al (2020) Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int 125(2):206\u2013214. https:\/\/doi.org\/10.1111\/bju.14944","journal-title":"BJU Int"},{"issue":"2","key":"4710_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2018.02.024","volume":"74","author":"N Fossati","year":"2018","unstructured":"Fossati N, Parker WP, Karnes RJ et al (2018) More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes with salvage radiotherapy for rising prostate-specific antigen after surgery: a long-term, multi-institutional analysis. Eur Urol 74(2):134\u2013137. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.024","journal-title":"Eur Urol"},{"issue":"6","key":"4710_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/pros.23491","volume":"78","author":"F Preisser","year":"2018","unstructured":"Preisser F, Bandini M, Marchioni M et al (2018) Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate 78(6):469\u2013475. https:\/\/doi.org\/10.1002\/pros.23491","journal-title":"Prostate"},{"issue":"1","key":"4710_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","volume":"76","author":"F Preisser","year":"2019","unstructured":"Preisser F, Chun FKH, Pompe RS et al (2019) Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol 76(1):106\u2013114. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.048","journal-title":"Eur Urol"},{"issue":"6","key":"4710_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/00365590903200524","volume":"43","author":"C Lindberg","year":"2009","unstructured":"Lindberg C, Davidsson T, Gudj\u00f3nsson S et al (2009) Extended pelvic lymphadenectomy for prostate cancer: will the previously reported benefits be reproduced in hospitals with lower surgical volumes? Scand J Urol Nephrol 43(6):437\u2013441. https:\/\/doi.org\/10.3109\/00365590903200524","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"4710_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","volume":"50","author":"A Briganti","year":"2006","unstructured":"Briganti A, Chun FK, Salonia A et al (2006) Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50(5):1006\u20131013. https:\/\/doi.org\/10.1016\/j.eururo.2006.08.015","journal-title":"Eur Urol"},{"key":"4710_CR51","doi-asserted-by":"publisher","unstructured":"Winter A, Vogt C, Weckermann D, et al (2011) [Complications of pelvic lymphadenectomy in clinically localised prostate cancer: different techniques in comparison and dependency on the number of removed lymph nodes]. Aktuelle Urol 42(3):179\u2013183. Komplikationsrate der Pelvinen Lymphadenektomie Beim Klinisch Lokalisierten Prostatakarzinom: Unterschiedliche Techniken im Vergleich und Abh\u00e4ngigkeit von der Anzahl Entfernter Lymphknoten. https:\/\/doi.org\/10.1055\/s-0031-1271389","DOI":"10.1055\/s-0031-1271389"},{"issue":"3","key":"4710_CR52","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2012.05.057","volume":"62","author":"F Montorsi","year":"2012","unstructured":"Montorsi F, Wilson TG, Rosen RC et al (2012) Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol 62(3):368\u2013381. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.057","journal-title":"Eur Urol"},{"issue":"2","key":"4710_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5173\/ceju.2022.0284","volume":"75","author":"A Porreca","year":"2022","unstructured":"Porreca A, Di Gianfrancesco L, Artibani W et al (2022) Robotic-assisted, laparoscopic, and open radical cystectomy: surgical data of 1400 patients from The Italian Radical Cystectomy Registry on intraoperative outcomes. Central Eur J Urol 75(2):135\u2013144. https:\/\/doi.org\/10.5173\/ceju.2022.0284","journal-title":"Central Eur J Urol"},{"issue":"6","key":"4710_CR54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1590\/s1677-5538.Ibju.2023.0349","volume":"49","author":"JM Gaya","year":"2023","unstructured":"Gaya JM, Uleri A, Sanz I et al (2023) Robot-assisted radical cystectomy and ileal conduit with Hugo(TM) RAS system: feasibility, setting and perioperative outcomes. Int Braz J Urol 49(6):787\u2013788. https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2023.0349","journal-title":"Int Braz J Urol"},{"issue":"9","key":"4710_CR55","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.asjsur.2023.04.030","volume":"46","author":"P Li","year":"2023","unstructured":"Li P, Meng C, Peng L et al (2023) Perioperative comparison between robot-assisted and laparoscopic radical cystectomy: an update meta-analysis. Asian J Surg 46(9):3464\u20133479. https:\/\/doi.org\/10.1016\/j.asjsur.2023.04.030","journal-title":"Asian J Surg"},{"key":"4710_CR56","doi-asserted-by":"publisher","first-page":"7631903","DOI":"10.1155\/2022\/7631903","volume":"2022","author":"P Castro","year":"2022","unstructured":"Castro P, Arantes PBO, Martins YMR et al (2022) Complications of extended pelvic lymph node dissection in patients undergoing minimally invasive radical prostatectomy: analysis and risk factors. Prostate Cancer 2022:7631903. https:\/\/doi.org\/10.1155\/2022\/7631903","journal-title":"Prostate Cancer"},{"key":"4710_CR57","unstructured":"Tullington JE, Blecker N (2025) Lower genitourinary trauma. StatPearls. StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC"},{"issue":"11","key":"4710_CR58","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","volume":"31","author":"Y Kohjimoto","year":"2024","unstructured":"Kohjimoto Y, Uemura H, Yoshida M et al (2024) Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol 31(11):1180\u20131222. https:\/\/doi.org\/10.1111\/iju.15545","journal-title":"Int J Urol"},{"issue":"4","key":"4710_CR59","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ju.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK et al (2024) Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol 211(4):509\u2013517. https:\/\/doi.org\/10.1097\/ju.0000000000003892","journal-title":"J Urol"},{"issue":"4","key":"4710_CR60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/ju.0000000000003890","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK et al (2024) Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol 211(4):526\u2013532. https:\/\/doi.org\/10.1097\/ju.0000000000003890","journal-title":"J Urol"},{"issue":"10","key":"4710_CR61","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N et al (2023) Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(10):1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"4710_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100518","volume":"7","author":"R Kanesvaran","year":"2022","unstructured":"Kanesvaran R, Castro E, Wong A et al (2022) Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open 7(4):100518. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100518","journal-title":"ESMO Open"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04710-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:31:00Z","timestamp":1772029860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04710-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4710"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04710-z","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}